

<b>FORM PTO-1449</b> <b>(Rev. 2-32)</b>	<b>U.S. Department of Commerce</b> <b>Patent and Trademark Office</b>	<b>Atty. Docket No.</b> 07-1009-WO-US	<b>Serial No.</b> 10/580,164
<p align="center"> <b>SUPPLEMENTAL          INFORMATION DISCLOSURE          STATEMENT BY APPLICANT</b>          (Use several sheets if necessary)       </p>		<b>Applicant:</b> Mark Ian Christie	
		<b>Filing Date:</b> May 18, 2006	<b>Group:</b> 1646

### U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
	6,274,711	08/14/01	Golstein, et al			

### FOREIGN PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Country	Class	Subclass	Translation Yes No

### OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

	Kotake, <i>et al.</i> , <i>IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis</i> , The Journal of Clinical Investigation, 103:1345-1352 (1999).
	Chabaud, <i>et al.</i> , <i>Contribution of Interleukin 17 to Synovium Matrix Destruction in Rheumatoid Arthritis</i> , Cytokine, 12:1092-1099 (2000).
EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.